NCT07075276 Liquid Phase Concentrated Growth Factor Versus Conventional Arthrocentesis in Temporomandibular Disc Displacement
| NCT ID | NCT07075276 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Horus University |
| Condition | Temporomandibular Disorders (TMD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2026-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 32 participants in total. It began in 2025-10-01 with a primary completion date of 2026-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to rigorously assess the effectiveness of LPCGF in the management of internal disc displacement in patients with TMD through a randomized clinical trial. By comparing LPCGF therapy with conventional arthrocentesis, this research looks to provide robust evidence on the efficacy, safety, and potential role of (LPCGF) as an alternative therapeutic choice for IDD.
Eligibility Criteria
Inclusion Criteria: * 1\. Adults aged 18-45 years. 2. Patients scored as (ASA I).9 3. Presence of complete or nearly complete set of natural dentition with Angle class I occlusion. 4. Diagnosed with unilateral involvement of disc displacement, according to the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD).10 5. Symptoms include one or more of the following: pain, joint sounds, and limited mandibular movement (Maximum Mouth Opening\< 40mm) 6. No prior surgical intervention for TMD. 7. Patient's willingness to participate and follow the study protocol. Exclusion Criteria: * 1\. TMJ pathology related to mechanical deformities 2. Psychiatric problems or presence of systemic diseases that may affect healing (e.g., uncontrolled diabetes, autoimmune disorders, hematologic or neurologic disorders, inflammatory or connective tissue disorders as well as rheumatological or previous infectious diseases, head and neck cancer). 3. Patient unwilling or has contraindication to MRI 4. Previous injections or surgical interventions of the TMJ. 5. Concurrent use of anticoagulants or anti-inflammatory medications within the last 30 days. 6. Pregnant or breastfeeding women. 7. History of trauma or infection in the TMJ region. 8. Allergy to local anesthetics or other components used in the study. 9. Patients diagnosed with (Disc Displacement with reduction with no pain or limited mandibular movements).
Contact & Investigator
Mohamed Ali Habib, Teaching Assistant
PRINCIPAL INVESTIGATOR
Horus University in Egypt - Faculty of dentistry
Frequently Asked Questions
Who can join the NCT07075276 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Temporomandibular Disorders (TMD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07075276 currently recruiting?
Yes, NCT07075276 is actively recruiting participants. Contact the research team at mbasiouny@horus.edu.eg for enrollment information.
Where is the NCT07075276 trial being conducted?
This trial is being conducted at Damietta, Egypt.
Who is sponsoring the NCT07075276 clinical trial?
NCT07075276 is sponsored by Horus University. The principal investigator is Mohamed Ali Habib, Teaching Assistant at Horus University in Egypt - Faculty of dentistry. The trial plans to enroll 32 participants.